Glaukos Corporation announced the commercial availability of Epioxa HD/Epioxa directly from Glaukos or through its specialty pharmaceutical distribution network. Epioxa offers an incision-free alternative to traditional corneal cross-linking procedures. According to the company, the topical therapy, catalyzed by enriched oxygen and light, is designed to reduce the pain associated with epithelium removal, streamline the procedure, and minimize recovery.

In related news, Glaukos has announced the launch of EpioxaCareConnect, a patient support program designed to simplify access to Epioxa cross-linking treatment and guide patients throughout their care journey. The new initiative aims to address common barriers to treatment by offering a centralized resource for access, reimbursement, and financial support. Through EpioxaCareConnect, patients and providers can receive assistance with benefit investigations, prior authorizations, appeals, and affordability programs—areas that often delay or complicate care.

A key feature of the program is personalized support. Each enrolled patient is paired with a dedicated Patient Access Liaison (PAL) who provides 1-on-1, non-medical guidance. PALs help patients navigate insurance processes, answer logistical questions, and coordinate next steps, including follow-up care such as second-eye treatment when needed.